Xcout Intel
Upflowy
Upflowy (now known as Psyke) is a software company whose main headquarters is located in Sydney, New South Wales, Australia.
Subscribe to see Upflowy’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Upflowy at a glance
Upflowy is a software company headquartered in Australia. It has raised at least $4.8M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $4M in February 2022. Xcout tracks 3 named people at Upflowy, including Guillaume Ang (Co-founder CEO).
Upflowy leadership
- Guillaume AngCo-founder CEO
- Alex GirardCo-founder CTO
- Matthew BrowneCo-founder CIO
Upflowy funding rounds
At least $4.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $4M | 1 named | |
| Seed | $780,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Upflowy competitors
A few of Upflowy's closest competitors — see the full list of competitors and alternatives →
HINDSITE Industries is a work management software company headquartered in Brisbane City, Queensland, that replaces paper and disconnected workflows with digital productivity systems.
Flowy provides a digital transformation platform that enables businesses to create forms, organize workflows, collect data, and manage documents without requiring developers. The platform serves organizations seeking to streamline internal processes, track team activities, and analyze data through embedded business intelligence tools.
Workflowy develops a minimalist note-taking and list-making productivity software designed to help users organize their thoughts and work.
ProcessFlow is a privately held company headquartered in Paris that delivers business process consulting and workflow optimization solutions.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Get Upflowy's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Upflowy in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access